Phase II Study of Dose-Adjusted EPOCH+/- Rituximab in Adults With Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma

ID Number 58-0056-09177

Principal Investigator(s)
Samir Parekh

Department(s) or Division(s)
Hematology and Medical Oncology


You are being asked to take part in this study because you have aggressive B-cell lymphoma.  The purpose of this study is to compare the good and/or bad effects of an experimental approach to treating your disease and to analyze your tumor using new scientific laboratory studies.  Many of the standard treatments for Burkitt lymphoma can cause severe side effects that may require a long stays in the hospital.  Our experience using this study treatment, Dose-Adjusted EPOCH +/- Rituximab (DA-EPOCH-R) has been that it has not been associated with the same severity of side effects or long durations in the hospital.  In addition, studies so far using DA-EPOCH-R in patients with your disease appear to be promising.  We hope to confirm these very good results in this study.

Contact Information
Lisa La
(212) 841-8615

Recruiting Patients: Yes